These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8841958)

  • 1. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared.
    Gsell W; Strein I; Riederer P
    J Neural Transm Suppl; 1996; 47():73-101. PubMed ID: 8841958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models.
    Van Dam D; Marescau B; Engelborghs S; Cremers T; Mulder J; Staufenbiel M; De Deyn PP
    Neurochem Int; 2005 Apr; 46(5):409-22. PubMed ID: 15737439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple biochemical deficits in both gray and white matter of Alzheimer brains.
    Gottfries CG; Bartfai T; Carlsson A; Eckernäs S; Svennerholm L
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):405-13. PubMed ID: 3797685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease--a comparative review.
    Gsell W; Strein I; Krause U; Riederer P
    J Neural Transm Suppl; 1997; 51():145-59. PubMed ID: 9470135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neurochemistry of Alzheimer's disease.
    Engelborghs S; De Deyn PP
    Acta Neurol Belg; 1997 Jun; 97(2):67-84. PubMed ID: 9246374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical aspects on aging and diseases with cognitive impairment.
    Gottfries CG
    J Neurosci Res; 1990 Dec; 27(4):541-7. PubMed ID: 2079715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia.
    Arai H; Kosaka K; Iizuka R
    J Neurochem; 1984 Aug; 43(2):388-93. PubMed ID: 6204013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are post-mortem biochemical studies of human brain worthwhile?
    Palmer AM; Lowe SL; Francis PT; Bowen DM
    Biochem Soc Trans; 1988 Aug; 16(4):472-5. PubMed ID: 2905309
    [No Abstract]   [Full Text] [Related]  

  • 9. Distribution of biogenic amines and their catabolites in brains from patients with Alzheimer's disease.
    Ebinger G; Bruyland M; Martin JJ; Herregodts P; Cras P; Michotte Y; Gommé L
    J Neurol Sci; 1987 Feb; 77(2-3):267-83. PubMed ID: 3819769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias.
    Casado A; Encarnación López-Fernández M; Concepción Casado M; de La Torre R
    Neurochem Res; 2008 Mar; 33(3):450-8. PubMed ID: 17721818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease: biological diagnosis.
    Ebinger G; Herregodts P; Michotte Y; Vanderheyden P; Vauqelin G
    Acta Neurol Belg; 1989; 89(3-4):132-4. PubMed ID: 2516958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia.
    Cacabelos R; Alvarez XA; Fernández-Novoa L; Franco A; Mangues R; Pellicer A; Nishimura T
    Methods Find Exp Clin Pharmacol; 1994 Mar; 16(2):141-51. PubMed ID: 8007743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of a number of biogenic amines and their metabolites in brain homogenates by gas chromatography--mass spectrometry.
    Herranen J; Huhtikangas A; Tirronen H; Halonen T; Huuskonen M; Reinikainen K; Riekkinen P
    J Chromatogr; 1984 May; 307(2):241-9. PubMed ID: 6736175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer's disease.
    Manuel I; Lombardero L; LaFerla FM; Giménez-Llort L; Rodríguez-Puertas R
    Neuroscience; 2016 Aug; 329():284-93. PubMed ID: 27223629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease. A critical review.
    Gottfries CG
    Compr Gerontol C; 1988 Dec; 2(1):47-62. PubMed ID: 3076510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cholinergic receptor system of the human brain: neurochemical and pharmacological aspects in aging and Alzheimer.
    Giacobini E; DeSarno P; Clark B; McIlhany M
    Prog Brain Res; 1989; 79():335-43. PubMed ID: 2685904
    [No Abstract]   [Full Text] [Related]  

  • 18. Brain muscarinic receptors in senile dementia.
    Rinne JO; Laakso K; Lönnberg P; Mölsä P; Paljärvi L; Rinne JK; Säkö E; Rinne UK
    Brain Res; 1985 Jun; 336(1):19-25. PubMed ID: 4005573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related changes in brain biogenic monoamines and monoamine oxidase.
    Petkov VD; Stancheva SL; Petkov VV; Alova LG
    Gen Pharmacol; 1987; 18(4):397-401. PubMed ID: 3038666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits.
    Bierer LM; Haroutunian V; Gabriel S; Knott PJ; Carlin LS; Purohit DP; Perl DP; Schmeidler J; Kanof P; Davis KL
    J Neurochem; 1995 Feb; 64(2):749-60. PubMed ID: 7830069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.